Please type a plus sign (+) inside this box ->	-/
ricass type a piece orgit ( ) manage and a	

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use integrit 1097/93. ON BOSTOCK

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

ž

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

Sheet 1 of

Complete if Known			
Application Number	10/749,631		
Filing Date	12-31-2003		
First Named Inventor	KLEEMANN		
Group Art Unit	1626		
Examiner Name			
Attorney Docket Number	DEAV2002/0094 - US - CNT		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Paten Number	t Document  Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
20		5,852,046		LANG, et al.	12-22-1998	
				<u> </u>		
					<u> </u>	
		<b>}</b>			<del></del>	
-					<del>                                     </del>	
					<del> </del>	
		<u> </u>				
				,		
					, ,	
		<u> </u>				

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Office	Foreign Patent Doc 3 Number4	cument Kind Code <sup>5</sup> (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
168		EP	0622356		KOJIMA, et al.	11-02-1994		
131		wo	99/43663		HAMANAKA, et al.	09-02-1999		
A		wo	00/71537		KARABELAS, et al.	11-30-2000		
		_		_		+		┼┤
								口
		<u> </u>				<del> </del>		+
			•				·	
								$\perp \perp$

Examiner Signature	Loleur +	1 11	Date Considered	2110/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with pext communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English tanguage Translation is attached.

Please type a plus sign (+) inside this box 🛶 🕡
lease type a bing aight ( ) mores and sev

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449B/PTO INFORMATION DISCLOSURE		Complete if Known			
				Application Number	10/749,631	
INFO	ORMATIC	D NC	ISCLOSURE	Filing Date	12-31-2003	
STA	TEMEN	T RY	APPLICANT	First Named Inventor	KLEEMANN	
OTATEMENT BY ALL ELOAM			AII LIOAIII	Group Art Unit	1626	
	(use as mai	ny sheets	as necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	DEAV2002/0094 - US - CNT	

Examiner Initials'  Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.  Everett, Chris, Haemolytic disease of the newborn - time to prevent unnecessary deaths, Comparative Medicine, The British Journal of General Practice, 2000, 50 (5), pg. 511  Lauer, et al., The Synthesis of Some Chloromethoxyquinolines, J. Amer. Chem. Soc., 1946, (68) pp. 126  SCHULTHEIS, et al., Targeted Disruption of the Murine Na+/H+ Exchanger Isoform 2 Gene Causes Rec Viability of Gastric Parietal Cells and Loss of Net Acid Secretion, Journal Clinical Investigation, Vol. 101, Number 6, March 1998, pp. 1243-1253.  Toyota, et al., Tandern Michael Addition-[3,3] Sigmatropic Rearrangement Processes, Part 2. Constuction Cyclopropa [3,4] pyrrolo [3,2-e] indol-4-one (CPI) Unit of Antitumour Antibiotic CC-1085, J. Chem. Soc. F. Trans. 1, (1992), (5), pgs. 547-552	1
Medicine, The British Journal of General Practice, 2000, 50 (5), pg. 511  Lauer, et al., The Synthesis of Some Chloromethoxyquinolines, J. Amer. Chem. Soc., 1946, (68) pp. 126  SCHULTHEIS, et al., Targeted Disruption of the Murine Na+/H+ Exchanger Isoform 2 Gene Causes Rec Viability of Gastric Parietal Cells and Loss of Net Acid Secretion, Journal Clinical Investigation, Vol. 101, Number 6, March 1998, pp. 1243-1253.  Toyota, et al., Tandem Michael Addition-[3,3] Sigmatropic Rearrangement Processes, Part 2. Constuction Cyclopropa [3,4] pyrrolo [3,2-e] indol-4-one (CPI) Unit of Antitumour Antibiotic CC-1065, J. Chem. Soc. F	<del></del>
SCHULTHEIS, et al., Targeted Disruption of the Murine Na+/H+ Exchanger Isoform 2 Gene Causes Rec Viability of Gastric Parietal Cells and Loss of Net Acid Secretion, Journal Clinical Investigation, Vol. 101, Number 6, March 1998, pp. 1243-1253.  Toyota, et al., Tandem Michael Addition-[3,3] Sigmatropic Rearrangement Processes, Part 2. Constuction Cyclopropa [3,4] pyrrolo [3,2-e] indol-4-one (CPI) Unit of Antitumour Antibiotic CC-1065, J. Chem. Soc. F	
Viability of Gastric Parletal Cells and Loss of Net Acid Secretion, Journal Clinical Investigation, Vol. 101, Number 6, March 1998, pp. 1243-1253.  Toyota, et al., Tandem Michael Addition-[3,3] Sigmatropic Rearrangement Processes, Part 2. Constuction Cyclopropa [3,4] pyrrolo [3,2-e] indol-4-one (CPI) Unit of Antitumour Antibiotic CC-1065, J. Chem. Soc. F	-1269
Cyclopropa [3,4] pyrrolo [3,2-e] indol-4-one (CPI) Unit of Antitumour Antibiotic CC-1065, J. Chem. Soc. F	ced
	of rkin
·	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.